Quest Diagnostics (NYSE:DGX) Cut to Neutral at Citigroup
Citigroup cut shares of Quest Diagnostics (NYSE:DGX – Free Report) from a buy rating to a neutral rating in a report published on Tuesday, MarketBeat reports. They currently have $185.00 target price on the medical research company’s stock. Several other brokerages have also recently issued reports on DGX. UBS Group increased their price objective on ...
Publicado el: 2025-03-07 07:48:51
Autor: MarketBeat News, Fuente: etfdailynews
Compartir: 
